Prognostic factors in uterine adenosarcoma: subanalysis of the SARCUT study.

Autor:	Mancari R; Gynecologic Oncology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy., Yusuf Y; Gynecologic Oncology Department, Tepecik Training and Research Hospital, Izmir, Türkiye., Macuks R; Latvian Oncology Center of Riga Eastern Clinical University Hospital, Riga, Latvia., Achimas-Cadariu P; Gynecologic Oncology Department, Institute of Oncology Prof. Dr. I Chiricuta, Cluj-Napoca, Romania.; Gynecologic Oncology Department, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj Napoca, Romania., Piek JM; Gynecologic Oncology Department, Catharina Ziekenhuis Department of Gynecology, Eindhoven, Netherlands., Sperduti I; Unit of Biostatistical, IRCCS Regina Elena National Cancer Institute, Rome, Italy., Corrado G; Gynecologic Oncology Unit, Department of Woman, Child and Public Health, Fondazione Policlinico Uni-versitario A. Gemelli IRCCS, Rome, Italy., Vizza E; Gynecologic Oncology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy., Zapardiel I; Gynecologic Oncology Unit, La Paz University Hospital, Madrid, Spain.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2024 May 21; Vol. 14, pp. 1393707. Date of Electronic Publication: 2024 May 21 (Print Publication: 2024).
DOI:	10.3389/fonc.2024.1393707
Abstrakt:	Objective: The purpose of the study was to analyse the role of prognostic factors on the risk of recurrence and overall survival of patients with uterine adenosarcoma. Methods: A retrospective international multicentre study involving 46 centres collected 32 cases of uterine adenosarcoma, and these cases were included in the present subanalysis. Clinical and demographic features and tumour characteristics were gathered, as well as information on treatment and relapse. Disease-free and overall survival were analysed. Results: The 5-year disease-free survival (DFS) was 85.3% and the 5-year overall survival (OS) rate was 89.5%. The risk factors significantly associated with overall survival were age (HR 1.09, 95% CI 1.03-1.15; p = 0.004) and FIGO stage II-III (HR 17.75, 95% CI 2.87-109.93; p = 0.002). Patients who experienced early relapse (within 12 months) had a tumour size >30 mm and advanced stage. The majority of recurred cases were treated with radiotherapy or surgery and obtained a good response rate. Conclusion: The most significant prognostic factors in uterine adenosarcoma were age and FIGO stage and, indirectly, tumour size at diagnosis. The use of secondary surgery and/or radiotherapy could help in prolonging the disease-free status of the patients. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. (Copyright © 2024 Mancari, Yusuf, Macuks, Achimas-Cadariu, Piek, Sperduti, Corrado, Vizza and Zapardiel.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu